Investing.com - Cellectis reported on Thursday first quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Cellectis announced earnings per share of $-0.64 on revenue of $3.83M. Analysts polled by Investing.com anticipated EPS of $-0.6804 on revenue of $14.41M.
Cellectis shares are down 62.44% from the beginning of the year, still down 81.91% from its 52 week high of $16.86 set on May 20, 2021. They are under-performing the Nasdaq which is down 27.32% from the start of the year.
Cellectis follows other major Healthcare sector earnings this month
Cellectis's report follows an earnings beat by J&J on April 19, who reported EPS of $2.67 on revenue of $23.43B, compared to forecasts EPS of $2.59 on revenue of $23.62B.
UnitedHealth had beat expectations on April 14 with first quarter EPS of $5.49 on revenue of $80.15B, compared to forecast for EPS of $5.36 on revenue of $78.73B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar